Literature DB >> 31039012

LI-RADS: Diagnostic Performance of Hepatobiliary Phase Hypointensity and Major Imaging Features of LR-3 and LR-4 Lesions Measuring 10-19 mm With Arterial Phase Hyperenhancement.

Federica Vernuccio1,2, Roberto Cannella3,4, Mathias Meyer1, Kingshuk Roy Choudhoury5, Fernando Gonzáles1,6, Fides R Schwartz1, Rajan T Gupta1, Mustafa R Bashir1,7, Alessandro Furlan3, Daniele Marin1.   

Abstract

OBJECTIVE. The purpose of this study was to determine the diagnostic performance of hepatobiliary phase hypointensity and Liver Imaging Reporting and Data System (LI-RADS) major imaging features in the diagnosis of hepatocellular carcinoma (HCC) in hepatic lesions with arterial phase hyperenhancement (APHE) measuring 10-19 mm in patients at high risk of HCC. MATERIALS AND METHODS. A composite reference standard of pathologic analysis and imaging follow-up was used. The diagnostic performance (sensitivity and specificity) of hepatobiliary phase hypointensity and LI-RADS major imaging features other than APHE for the diagnosis of HCC was assessed and compared by means of a logistic regression model. RESULTS. This retrospective dual-institution study included 189 LI-RADS LR-3 and LR-4 lesions measuring 10-19 mm and having APHE in 144 consecutively registered patients (96 men, 48 women; mean age, 58 years). Hepatobiliary phase hypointensity had significantly higher sensitivity (84% [92/109], p < 0.00001) than major imaging features in the diagnosis of HCC but lower specificity (84% [67/80]; p = 0.01). However, hepatobiliary phase hypointensity in LR-3 observations measuring 10-19 mm and having APHE had moderately elevated sensitivity (73% [44/60]) and specificity (85%, 64/75). All three major imaging features had high specificity for the diagnosis of HCC, including 95% (76/80) for washout, 100% (80/80) for enhancing capsule, and 99% (79/80) for threshold growth. CONCLUSION. Major imaging features have high specificity for the diagnosis of HCC in lesions measuring 10-19 mm that have APHE. The finding of hepatobiliary phase hypointensity significantly improves sensitivity while moderately high specificity is maintained for the diagnosis of HCC in LR-3 lesions measuring 10-19 mm that exhibit APHE.

Entities:  

Keywords:  MRI; cirrhosis; gadoxetate disodium; gadoxetic acid; hepatocellular carcinoma; liver; sensitivity; specificity

Year:  2019        PMID: 31039012     DOI: 10.2214/AJR.18.20979

Source DB:  PubMed          Journal:  AJR Am J Roentgenol        ISSN: 0361-803X            Impact factor:   3.959


  11 in total

1.  Tumor size-based validation of contrast-enhanced ultrasound liver imaging reporting and data system (CEUS LI-RADS) 2017 for hepatocellular carcinoma characterizing.

Authors:  Jia-Min Pan; Wei Chen; Yan-Ling Zheng; Mei-Qing Cheng; Dan Zeng; Hui Huang; Yang Huang; Xiao-Yan Xie; Ming-De Lu; Ming Kuang; Hang-Tong Hu; Li-Da Chen; Wei Wang
Journal:  Br J Radiol       Date:  2021-10-01       Impact factor: 3.629

2.  Role of LI-RADS Indeterminate Observations in the Risk of Hepatocellular Carcinoma after HCV Eradication with Direct-Acting Antivirals.

Authors:  Federica Vernuccio; Roberto Cannella; Giuseppe Cabibbo; Silvia Greco; Ciro Celsa; Francesco Matteini; Paolo Giuffrida; Massimo Midiri; Vito Di Marco; Calogero Cammà; Giuseppe Brancatelli
Journal:  Diagnostics (Basel)       Date:  2022-05-10

3.  Can modified LI-RADS increase the sensitivity of LI-RADS v2018 for the diagnosis of 10-19 mm hepatocellular carcinoma on gadoxetic acid-enhanced MRI?

Authors:  Sidong Xie; Yao Zhang; Jingbiao Chen; Ting Jiang; Weimin Liu; Dailin Rong; Lin Sun; Linqi Zhang; Bingjun He; Jin Wang
Journal:  Abdom Radiol (NY)       Date:  2021-11-13

Review 4.  Spectrum of liver lesions hyperintense on hepatobiliary phase: an approach by clinical setting.

Authors:  Federica Vernuccio; Domenico Salvatore Gagliano; Roberto Cannella; Ahmed Ba-Ssalamah; An Tang; Giuseppe Brancatelli
Journal:  Insights Imaging       Date:  2021-01-12

5.  Radiomics Model Based on Gadoxetic Acid Disodium-Enhanced MR Imaging to Predict Hepatocellular Carcinoma Recurrence After Curative Ablation.

Authors:  Ling Zhang; Peiqiang Cai; Jingyu Hou; Ma Luo; Yonggang Li; Xinhua Jiang
Journal:  Cancer Manag Res       Date:  2021-03-25       Impact factor: 3.989

6.  Conventional, functional and radiomics assessment for intrahepatic cholangiocarcinoma.

Authors:  Vincenza Granata; Roberta Fusco; Andrea Belli; Valentina Borzillo; Pierpaolo Palumbo; Federico Bruno; Roberta Grassi; Alessandro Ottaiano; Guglielmo Nasti; Vincenzo Pilone; Antonella Petrillo; Francesco Izzo
Journal:  Infect Agent Cancer       Date:  2022-03-28       Impact factor: 2.965

Review 7.  A Narrative Review on LI-RADS Algorithm in Liver Tumors: Prospects and Pitfalls.

Authors:  Federica De Muzio; Francesca Grassi; Federica Dell'Aversana; Roberta Fusco; Ginevra Danti; Federica Flammia; Giuditta Chiti; Tommaso Valeri; Andrea Agostini; Pierpaolo Palumbo; Federico Bruno; Carmen Cutolo; Roberta Grassi; Igino Simonetti; Andrea Giovagnoni; Vittorio Miele; Antonio Barile; Vincenza Granata
Journal:  Diagnostics (Basel)       Date:  2022-07-07

Review 8.  Current Imaging Diagnosis of Hepatocellular Carcinoma.

Authors:  Evangelos Chartampilas; Vasileios Rafailidis; Vivian Georgopoulou; Georgios Kalarakis; Adam Hatzidakis; Panos Prassopoulos
Journal:  Cancers (Basel)       Date:  2022-08-18       Impact factor: 6.575

9.  Radiomics Analysis on Gadoxetate Disodium-Enhanced MRI Predicts Response to Transarterial Embolization in Patients with HCC.

Authors:  Roberto Cannella; Carla Cammà; Francesco Matteini; Ciro Celsa; Paolo Giuffrida; Marco Enea; Albert Comelli; Alessandro Stefano; Calogero Cammà; Massimo Midiri; Roberto Lagalla; Giuseppe Brancatelli; Federica Vernuccio
Journal:  Diagnostics (Basel)       Date:  2022-05-24

10.  Consensus report from the 8th International Forum for Liver Magnetic Resonance Imaging.

Authors:  Christoph J Zech; Ahmed Ba-Ssalamah; Thomas Berg; Hersh Chandarana; Gar-Yang Chau; Luigi Grazioli; Myeong-Jin Kim; Jeong Min Lee; Elmar M Merkle; Takamichi Murakami; Jens Ricke; Claude B Sirlin; Bin Song; Bachir Taouli; Kengo Yoshimitsu; Dow-Mu Koh
Journal:  Eur Radiol       Date:  2019-08-05       Impact factor: 5.315

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.